Literature DB >> 6707192

Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid.

M F Saad, H A Fritsche, N A Samaan.   

Abstract

This study was conducted to compare the diagnostic and prognostic values of calcitonin (CT) and carcinoembryonic antigen (CEA) measurements in patients with medullary carcinoma of the thyroid (MCT). Plasma CEA, basal CT (BCT), and peak CT (PCT) levels after pentagastrin stimulation were determined in 15 patients with occult familial MCT before treatment. CEA was elevated in 11 patients (73%), BCT in 8 patients (53%), and PCT in all patients. The prognostic values of serial CEA and BCT determinations were studied in 24 other MCT patients followed for a period of 1.5-8 yr. These patients were divided into 2 groups; group I consisted of 11 patients with normal serial CEA levels, and group II consisted of 13 patients with persistently elevated CEA levels. In group I, 2 patients (18%) developed metastases compared with 10 patients (77%) in group II (P less than 0.001). Elevated BCT levels were found in all patients with metastases as well as in 63% of patients with no evidence of disease. When CEA time curves were studied, three patterns could be identified: 1) a steep slope with rapidly rising CEA levels in patients with rapidly progressive disease, 2) a flat slope in patients with no metastasis or nonprogressive disease, and 3) an intermediate type of slope in patients with slowly progressive disease. Slope analysis of BCT time curves was not done because of marked fluctuations in BCT levels. PCT after pentagastrin stimulation remains the best diagnostic marker for MCT. However, CEA may be a better prognostic indicator, as it discriminated more efficiently between patients with and without metastasis. Slope analysis of CEA time curve and calculation of the doubling time are recommended, as they correlated well with the course of the disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6707192     DOI: 10.1210/jcem-58-5-889

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma.

Authors:  Alicia Algeciras-Schimnich; Carol M Preissner; J Paul Theobald; Mary S Finseth; Stefan K G Grebe
Journal:  J Clin Endocrinol Metab       Date:  2008-12-16       Impact factor: 5.958

2.  Medullary thyroid cancer, papillary thyroid microcarcinoma and Graves' disease: an unusual clinical coexistence.

Authors:  G Mazziotti; M Rotondi; G Manganella; R Franco; V Colantuoni; G Amato; C Carella
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

3.  Ultrastructural study of poorly differentiated medullary carcinoma of the thyroid.

Authors:  K Kakudo; A Miyauchi; S Katayama; K Watanabe
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

4.  Immunohistochemical study of medullary thyroid carcinoma: relationship of clinical features to prognostic factors in 36 patients.

Authors:  H Takami; T Bessho; T Kameya; T Mimura; K Ito; O Abe; Y Hosoda; J Shikata
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

5.  99mTc(V)-dimercaptosuccinic acid scintigraphy for medullary thyroid carcinoma.

Authors:  A Miyauchi; K Endo; H Ohta; K Torizuka; F Matsuzuka; A Kobayashi; K Kuma; M Maeda
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

Review 6.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 7.  The utility of some modern techniques in understanding thyroid pathology.

Authors:  Virginia A LiVoisi
Journal:  Endocr Pathol       Date:  1990-06       Impact factor: 3.943

8.  MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical-pathological features and outcome.

Authors:  Francesca Galuppini; Loris Bertazza; Susi Barollo; Elisabetta Cavedon; Massimo Rugge; Vincenza Guzzardo; Diana Sacchi; Sara Watutantrige-Fernando; Federica Vianello; Caterina Mian; Gianmaria Pennelli
Journal:  Virchows Arch       Date:  2017-08-31       Impact factor: 4.064

9.  Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma.

Authors:  N Neuhold; F Längle; M Gnant; U Hollenstein; B Niederle
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

10.  Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma: a study of 53 cases.

Authors:  Lenine G Brandão; Beatriz G Cavalheiro; Consuelo R Junqueira
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.